How would you deploy a combination of tissue-based NGS and ctDNA to potentially provide a more detailed roadmap for targeted therapy and supplementary prognostic information?

How would you deploy a combination of tissue-based NGS and ctDNA to potentially provide a more detailed roadmap for targeted therapy and supplementary prognostic information?

How would you deploy a combination of tissue-based NGS and ctDNA to potentially provide a more detailed roadmap for targeted therapy and supplementary prognostic information? Why are the results from these two tests sometimes divergent in the same patient?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Razelle Kurzrock, MD

Razelle Kurzrock, MD

Chief, Division of Hematology and Oncology
UCSD School of Medicine
Senior Deputy Director, Clinical Science
Director, Center for Personalized Cancer Therapy
Director, Clinical Trials Office
UCSD Moores Cancer Center
San Diego, California